MOSCOW (Reuters) – The Russian Direct Investment Fund (RDIF) and the Uzbek pharmaceutical company Laxisam have agreed to supply up to 35 million doses of Sputnik V vaccine to Uzbekistan, RDIF said on Friday.
After receiving approval from the regulatory authorities of Uzbekistan, in 2020 up to 10 million doses of the vaccine can be supplied to the country, up to 25 million doses in 2021, the report said.
In August, the Sputnik V vaccine produced by the N.N. N.F. Gamaleya received a registration certificate from the Russian Ministry of Health, becoming the first registered coronavirus vaccine in the world.
Earlier, RDIF negotiated the supply of vaccines to Kazakhstan, Mexico, Brazil and India.
(Gleb Stolyarov. Edited by Anastasia Teterevleva)